In this exploratory real-world cohort of patients with advanced HF and refractory congestion, both outpatient furosemide strategies were associated with short-term decongestion, with differences observed in symptomatic response.
Abstract
Objectives: The objective of this study was to explore differences in short-term clinical response, renal outcomes, and healthcare resource utilization between two non-equivalent outpatient furosemide strategies: high-dose oral solution and subcutaneous administration. Methods: This retrospective observational study included 108 consecutive outpatients with advanced heart failure (HF) and diuretic resistance treated between January 2018 and December 2024. Patients received furosemide for 5 days as oral solution (250 mg/day; n = 81) or subcutaneous infusion via elastomeric pump (100 mg/day; n = 27). Primary endpoints were changes in functional status (NYHA [New York Heart Association] class), body weight, and renal function, assessed by changes in serum creatinine and estimated glomerular filtration rate and by clinically relevant worsening renal function criteria. Secondary endpoints included NT-proBNP changes and unplanned healthcare utilization at 30 days. Results: Both strategies were associated with short-term decongestion. Weight decreased similarly in both groups, with no difference in the proportion of patients achieving weight loss (oral 90% vs. subcutaneous 89%; p = 0.854). Functional improvement was more frequently observed in the oral-solution group (99% vs. 89%; p = 0.019). Renal outcomes were comparable between strategies, with no significant changes in eGFR and a similar proportion of patients experiencing a serum creatinine increase ≥0.3 mg/dL (25.9% vs. 22.2%; p = 0.85). No significant differences were observed in NT-proBNP changes. HF-related healthcare encounters decreased during the 30 days following treatment compared with the preceding 30-day period in the oral-solution group, whereas no significant within-group change was observed in the subcutaneous group. Conclusions: In this exploratory real-world cohort of patients with advanced HF and refractory congestion, both outpatient strategies were associated with short-term decongestion, with differences observed in symptomatic response. These findings are hypothesis-generating and warrant confirmation in prospective studies using comparable dosing strategies.
BACKGROUND
Patients hospitalized for heart failure often require prolonged intravenous diuretic therapy, contributing to costs and risks associated with inpatient care.
OBJECTIVES
We evaluated whether an early discharge strategy using subcutaneous furosemide delivered via a wearable minipump could increase days alive...
Ross T. Campbell, J. Osmanska, K. Docherty et al.· Journal of the American Coll...· 1 citation
Thiazide-only therapy was associated with the lowest mortality, while loop and combined diuretic therapy were linked to increased mortality and HF-rehospitalization, and Randomized trials investigating long-term diuretic therapy in HFmrEF patients are needed.
A. Schmitt, M. Behnes, M. Reinhardt et al.· Current Medical Research and...· 0 citations
Both dosing methods were effective in relieving symptoms of acute decompensated heart failure: Continuous infusion produced greater diuresis, while bolus dosing also remained effective.
Balakrishna Vuyyala, Shaik Harun Rasheed, N. Raghunandan et al.· International journal of res...· 0 citations
The observed dose-response relationship supports consideration of D2D time as a potential systems-level quality metric, warranting prospective validation, and suggests amplification of the survival gradient in registries with higher baseline mortality rates.
M. Ghozali, N. D. Putri· European Heart Journal, Supp...· 0 citations
BACKGROUND
Worsening heart failure (WHF) carries high short-term morbidity and mortality. Spot urinary sodium (NaU) is increasingly used to assess diuretic response but does not account for chronic loop diuretic exposure.
OBJECTIVES
To determine whether a urinary sodium-to-furosemide index (NaU/F) improves short-term...
L. Burgos, M. A. De Bortoli, R. Barovila et al.· Heart & lung : the journal o...· 0 citations
In this open-label, proof-of-concept study, empagliflozin was associated with improved short-term natriuretic indices over 10 days in diabetic patients with decompensated cirrhosis and refractory ascites, without serious adverse events.
Rong Shi, Yuan Gao, Yun-Yi Gao et al.· Journal of Gastrointestinal...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.